Deep Brain Stimulation (DBS) For Parkinson's Disease: Caudal Zona Incerta Versus Subthalamic Nucleus

Sponsor
Charite University, Berlin, Germany (Other)
Overall Status
Unknown status
CT.gov ID
NCT00888095
Collaborator
(none)
70
1
2
36
1.9

Study Details

Study Description

Brief Summary

The aim of this study is to analyze the effects of two different targets of deep brain stimulation: caudal Zona incerta and Nucleus subthalamicus. The present study will investigate the effects of DBS using a blind, randomized and stratified design in patients with Parkinson's disease.

Condition or Disease Intervention/Treatment Phase
  • Procedure: deep brain stimulation
N/A

Detailed Description

Parkinson's Disease (PD) is a severe neurological movement disorder comprising the triad of symptoms of bradykinesia, rigidity and tremor. It can be effectively treated with dopaminergic replacement therapy in the early course of the disease; however, after 5-10 years medical therapy is insufficient in the majority of patients. Since the early 90s the implantation of electrodes into the Nucleus subthalamicus (STN), (deep brain stimulation; DBS) has been established. DBS in PD- patients provides a definite and longlasting relief of motor symptoms and impaired quality of life compared to optimized medical treatment (Deuschl et al. 2006). Conventionally, electrodes are implanted into STN but other targets such as the pedunculopontine nucleus or the Zona incerta (ZI) have been reported to be useful. Importantly, the ZI has a key role in connection loops from the basal ganglia, thalamic regions and cortex. Retrospective studies of DBS-treated patients show relief of symptoms in DBS- treated PD patients, with the contacts of the electrodes being located to the ZI (Voges et al., 2002; Hamel et al., 2003a, 2003b). However, no prospective randomized studies analysing the effect of bilateral DBS comparing the targets of the caudal ZI (cZI) and STN are available. Therefore, the present study will investigate the effect and tolerance of DBS in both targets in a blind, randomized and stratified design in a total of 70 PD patients (see below for inclusion end exclusion criteria). The impairment of movement and quality of life will be assessed via established scales. Effects, tolerance and side effects of DBS will be monitored closely and re-assessed for a period of twelve months. Primary study criteria include UPDRS-III and quality of life.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
The Clinical Effect of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) Versus Bilateral Deep Brain Stimulation of the Caudal Zona Incerta (cZI-DBS) in Patients With Idiopathic Parkinson's Disease
Study Start Date :
Jul 1, 2010
Anticipated Primary Completion Date :
Jul 1, 2013
Anticipated Study Completion Date :
Jul 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

caudal Zona incerta (cZI)

Procedure: deep brain stimulation
electrode implantation in either STN or cZI

Experimental: 2

Nucleus subthalamicus (STN)

Procedure: deep brain stimulation
electrode implantation in either STN or cZI

Outcome Measures

Primary Outcome Measures

  1. Improvement of scores (UPDRS III, PDQ-39) in Stim-ON and Med-OFF in a standard clinical check-up (CAPSIT) 12 and 24 months after operation compared to primary inclusion examination [24 months]

Secondary Outcome Measures

  1. Changes in dysarthria, other symptoms (subitems of UPDRS-III), dyskinesia (UPDRS-IV), impairment of gait, on-off fluctuations [24 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Idiopathic Parkinson's disease (criteria of the British Brain Bank: L-DOPA- or Apomorphin-sensitivity of more than 30% or typical Parkinsonian tremor while resting)

  • duration of disease > 18 months

  • age between 18 and 75 Jahren

  • relevant disablement in daily activities/ impairment despite medical mental therapy

  • informed and signed consent of the patient

Exclusion Criteria:
  • major depression with suicidal thoughts (Becks Depressions Inventory-Score > 25); depressions in the past are no exclusion criterion

  • Mattis Dementia Rating Scale-score < 130

  • stereotactic brain operations in the past

  • significant brain atrophy

  • increased bleeding tendency

  • reduced infection defense

  • relevant cerebrovascular disease

  • acute psychosis (benign and/or hallucinations in the past are no exclusion criterion)

  • a physical and/or mental illness which is likely to affect the study procedures in a negative way (e.g., cancer with reduced life expectancy)

  • abuse of drugs or alcohol

  • female study participants of child- bearing age without adequate contraception

  • women during pregnancy or lactation

  • no sufficient knowledge of the German language to answer the questionnaires

  • other surgical contraindications

  • participation in another clinical trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Neurology and Neurosurgery Berlin Germany

Sponsors and Collaborators

  • Charite University, Berlin, Germany

Investigators

  • Principal Investigator: Andreas R Kupsch, MD, Department of Neurology, Charité

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00888095
Other Study ID Numbers:
  • DBS in the caudal Zona incerta
First Posted:
Apr 24, 2009
Last Update Posted:
Jul 22, 2009
Last Verified:
Jul 1, 2009

Study Results

No Results Posted as of Jul 22, 2009